

The 11th International Forum of The Japanese Society of Gastroenterology

JSGE-IASL (International Association for the Study of the Liver) Joint Session

DAY2

Time & Date : 9 : 00~17 : 05, Friday, April 22, 2022

Place : Room 6 (3F, Room "Grace", Keio Plaza Hotel Tokyo)

Main Theme : Dream of Hepatology

Opening Remarks (9 : 00~9 : 10)

Kwang-Hyub Han (National Evidence-based Healthcare Collaborating Agency,
Republic of Korea)

Enomoto Nobuyuki (First Department of Internal Medicine, Faculty of
Medicine, University of Yamanashi, Japan)

1. HCV : Eradication of HCV death

(9 : 10~10 : 10)

Moderators : Jean-Michel Pawlotsky (Department of Virology, Henri Mondor University Hospital,
France)

Raymond Chung (Liver Center, GI Division, Massachusetts General Hospital,
Harvard Medical School, USA)

Masayuki Kurosaki (Department of Gastroenterology and Hepatology, Musashino
Red Cross Hospital, Japan)

- | | |
|-------|--|
| IF1-1 | Impacts of the COVID-19 pandemic on HCV elimination
Jean-Michel Pawlotsky (Department of Virology, Henri Mondor University
Hospital, France) |
| IF1-2 | Problems with HCV treatment – Refractory HCV and clinical courses after SVR –
Michio Imamura (Department of Gastroenterology and Metabolism, Hiroshima
University, Japan) |
| IF1-3 | Mechanisms of hepatocarcinogenesis after HCV cure
Raymond Chung (Liver Center, GI Division, Massachusetts General Hospital,
Harvard Medical School, USA) |
| IF1-4 | Strategies towards the eradication of HCV death : Treatment of special
population (prior DAA failure) and the identification of high-risk cases for HCC
after SVR
Masayuki Kurosaki (Department of Gastroenterology and Hepatology,
Musashino Red Cross Hospital, Japan) |

2. HBV : Elimination of HBV infection

(10 : 10~11 : 30)

Moderators : Sang Hoon Ahn (Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Republic of Korea)

Jia-Horng Kao (Hepatitis Research Center, National Taiwan University Hospital, Taiwan)

Yasuhito Tanaka (Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Japan)

- IF2-1 Update on new HBV drugs in development
Sang Hoon Ahn (Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Republic of Korea)
- IF2-2 A novel, small anti-HBV compound reduces HBsAg and HBV DNA by destabilizing HBV RNA
Yasuhito Tanaka (Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Japan)
- IF2-3 Elimination of HBV infection in Taiwan
Jia-Horng Kao (Hepatitis Research Center, National Taiwan University Hospital, Taiwan)
- IF2-4 A novel therapeutic option for HBV elimination using additional immunomodulatory effects of nucleotide analogs
Kazumoto Murata (Division of Virology, Department of Infection and Immunity, Jichi Medical University, Japan)
- IF2-5 What do we need for functional cure of HBV infection?
Henry Lik Yuen Chan (Union Hospital/The Chinese University of Hong Kong, Hong Kong)

3. Steatohepatitis : Elucidation of the mechanism

(14 : 15~15 : 00)

Moderators : Jacob George (Storr Liver Centre, The Westmead Institute of Medical Research, Westmead Hospital and University of Sydney, Australia)

Takumi Kawaguchi (Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan)

- IF3-1 Impact of MAFLD on Intra- and Extrahepatic Events in Patients with Fatty Liver
Takumi Kawaguchi (Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan)
- IF3-2 Understanding lean MAFLD : Metabolic flexibility and metabolic adaptation
Jacob George (Storr Liver Centre, The Westmead Institute of Medical Research, Westmead Hospital and University of Sydney, Australia)

- IF3-3 Incidence of CVD in NAFLD/MAFLD patients : a retrospective nationwide claims database study in Japan.
Masato Yoneda (Department of Gastroenterology and Hepatology, Yokohama City University, Japan)

4. Cirrhosis : Endeavor for control
(15 : 00~16 : 00)

Moderators : Jordi Gracia-Sancho (Liver Vascular Biology, IDIBAPS Biomedical Research Institute & CIBEREHD, Spain)

Thomas Berg (Division of Hepatology, Department of Medicine II ; Leipzig University Medical Center, Germany)

Hitoshi Yoshiji (Department of Gastroenterology, Nara Medical University, Japan)

- IF4-1 Portal hypertension in CLD : molecular mechanisms and therapeutic opportunities
Jordi Gracia-Sancho (Liver Vascular Biology, IDIBAPS Biomedical Research Institute & CIBEREHD, Spain)
- IF4-2 CTGF secreted from liver sinusoidal endothelial cells has an essential role in liver fibrosis
Hayato Hikita (Department of Gastroenterology and Hepatology, Osaka University, Graduate School of Medicine, Japan)
- IF4-3 The role of G-CSF in the treatment of acute-on-chronic liver failure (ACLF)
Thomas Berg (Division of Hepatology, Department of Medicine II ; Leipzig University Medical Center, Germany)
- IF4-4 Liver cirrhosis : endeavor for control in Japan
Hitoshi Yoshiji (Department of Gastroenterology, Nara Medical University, Japan)

5. Hepatocellular Carcinoma : Evolution of the new treatment
(16 : 00~17 : 00)

Moderators : Markus Peck-Radosavljevic (Innere Medizin & Gastroenterologie, Klinikum Klagenfurt, Austria)

Kwang-Hyub Han (National Evidence-based Healthcare Collaborating Agency)

Taro Yamashita (Department of General Medicine, Kanazawa University Hospital, Japan)

- IF5-1 Progress in the Treatment of Hepatocellular Carcinoma (HCC)
Markus Peck-Radosavljevic (Innere Medizin und Gastroenterologie, Klinikum Klagenfurt, Austria)
- IF5-2 Recent advances of systemic therapy for hepatocellular carcinoma in Japan
Kaoru Tsuchiya (Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan)

